TOPIC 319 PHASE I; TECHNOLOGY TO GENERATE ANTI PEPTICE CAPTURE REAGENS AFFINITY E

主题 319 第一阶段；

• 批准号: 8762565
• 负责人: MARK MORRIS
• 金额: $ 19.96万
• 依托单位: BASE PAIR BIOTECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-13 至 2014-06-12
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8762565
• 关键词: Affinity; Biological Assay; Communities; Contracts; Development; Evaluation; Immunoprecipitation; Ligands; Malignant Neoplasms; Measurement; Peptides; Performance; Phase; Private Sector; Production; Public Sector; Reagent; Running; Small Business Innovation Research Grant; Specificity; Technology; Testing; Validation; Work; aptamer; cost effectiveness; improved; novel

The stated Phase I activities and expected deliverables of this SBIR Contract include: 1) Development of proof-of-concept technologies that reliably generate anti-peptide capture reagents that can immunoprecipitate the target peptides; 2) Demonstrate that the capture reagents developed can reproducibly immunoprecipitate the target peptides; 3) Work with the CPTC community, private and public sector to identify minimum characterization criteria for validation of the assays; 4) Generate affinity reagents to at least ten proteotypic peptides and demonstrate high affinity, specificity and immunoprecipitation performance; 5) Make available to NCI sufficient reagents to perform 10 test runs for each of the ten peptides for independent evaluation; 6) Present findings to an NCI CPTC Evaluation Panel demonstrating how the capture reagents have improved cost effectiveness and throughput capabilities in production.

本SBIR合同规定的第一阶段活动和预期可交付成果包括：1）开发 可靠地产生抗肽捕获试剂的概念验证技术， 免疫沉淀靶肽; 2）证明开发的捕获试剂可以重复地 免疫沉淀靶肽; 3）与CPTC社区，私营和公共部门合作， 确定用于验证测定的最低表征标准; 4）产生亲和试剂，以至少 10种蛋白质型肽，并显示出高亲和力、特异性和免疫沉淀性能; 5） 向NCI提供足够的试剂，以便对10种肽中的每一种进行10次测试运行， 6）向NCI CPTC评估小组展示结果，证明捕获试剂如何 提高了生产中的成本效益和生产能力。